Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

BACKGROUND: Cixutumumab, a monoclonal antibody targeting insulin-like growth factor I receptor, did not improve undetectable PSA rate at 28 weeks when combined with androgen deprivation in the randomized phase II SWOG S0925 trial for patients with new metastatic hormone-sensitive prostate cancer. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Risa L., Duong, Mai T., Tangen, Catherine M., Agarwal, Neeraj, Cheng, Heather H., Vogelzang, Nicholas J., Hussain, Maha, Thompson, Ian M., Quinn, David I., Yu, Evan Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423720/
https://www.ncbi.nlm.nih.gov/pubmed/32055002
http://dx.doi.org/10.1038/s41391-020-0210-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423720/
https://www.ncbi.nlm.nih.gov/pubmed/32055002
http://dx.doi.org/10.1038/s41391-020-0210-x

Ejemplares similares